BridgeBio Pharma (BBIO) Stock Price & Analysis

BBIO$77.36-0.94 -1.20%
BiotechnologyLarge CapGrowth Stock
Compare
Market cap$15.07BEnterprise value$16.13BRevenue (TTM)$945.54MMarket positionTop 25%

Score

56
Neutral
Value
39
Quality
30
Growth
98

AI Analysis

Snapshot

BridgeBio Pharma is a growth-led story right now — Growth 98/100 is the pillar doing the heavy lifting (overall 56/100) in Biotechnology. Under the hood: revenue compounding ~775% annually over recent years. Street targets still imply ~46% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

39
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

98
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

30
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

BridgeBio Pharma, Inc. (BBIO) last printed $77.36. Equity value is $15.07B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$0.00$0.00$40.56M$8.25M$69.72M$77.65M$9.3M$221.9M$502.08M

About

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

BridgeBio Pharma (BBIO) Stock Price & Analysis

BBIO price $77.36 -0.94 -1.20%

Ticker
BBIO
Price
$77.36
Change
-0.94 -1.20%
Market cap
$15.07B
Forward P/E
42.66
Dividend yield
0.00%
Beta
0.97
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
56
Value
39
Quality
30
Growth
98

Stocklytics score rationale: value 39, quality 30, growth 98.

AI Score 30. BridgeBio Pharma, Inc. has a high price of $74.95 with a market cap of $14.6 billion, but it faces significant challenges with a net profit margin of -60.3% and a price-to-sales ratio of 15.4

Fair value

BBIO fair value $49.63. Price $77.36. Price is 56% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value is the earnings value from next-twelve-months EPS times 27.4, a blend of the industry median and the stock's own 10-year median. A cash-flow value is not available for this stock. How we calculate it →

Compare BBIO

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-02-23—-0.59—310.85M
2026-10-29-0.42-0.54353.17M293.47M
2026-08-10-0.78-0.58243.68M220.91M
2026-05-07-0.84-0.68194.51M178.07M
2026-02-24-1.00-0.71154.18M146.84M
2025-10-29-0.95-0.88120.70M148.15M
2025-08-05-0.95-0.83110.56M108.13M
2025-04-29-0.88-1.00116.63M68.41M
2025-02-20-1.31-1.095.88M4.04M
2024-11-12-0.86-1.032.73M67.32M
2024-08-01-0.39-1.092.17M3.96M
2024-05-02-0.20-0.71211.12M7.26M
2024-02-22-0.96-0.951.75M6.23M
2023-11-02-1.08-0.864.09M4.26M
2023-08-03-0.98-0.861.64M2.99M
2023-05-04-0.92-0.841.83M3.37M
2023-02-23-0.87-0.861.87M4.52M
2022-11-03-0.93-1.02338.00K4.09M
2022-08-04-0.07-0.5673.75M27.19M
2022-05-05-1.19-1.131.69M4.70M
2022-02-24-1.01-0.8312.89M21.56M
2021-11-04-1.06-0.912.34M15.10M
2021-08-05-0.66-0.9354.02M34.84M
2021-05-06-1.18-0.87462.00K14.75M
2021-02-25-1.01-0.86122.00K16.93M
2020-11-05-0.98-0.978.13M7.63M
2020-08-11-1.03-0.79——
2020-05-13-0.78-0.69——
2020-03-02-0.62-0.7013.82M15.60M
2019-11-07-0.51-0.5526.74M28.84M
2019-08-14-3.46-0.52——
2019-06-28-0.42———
2019-03-31-0.51———
2018-09-30-0.34———
2018-06-30-0.29———
2018-03-31-0.37———

Dividends

Yield 0.00%. Payout ratio —. Frequency —.

Safety score 24/100 · At risk. Payout ratio is not reported, so this part stays neutral. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-30Apuli MaricelSell2.00K$72.85145.70K
2026-09-17Kumar NeilSell8.72K$69.01601.87K
2026-09-17Kumar NeilSell1.28K$69.5788.98K
2026-08-19Kumar NeilSell8.10K$83.86679.26K
2026-08-19Kumar NeilSell1.80K$84.69152.44K
2026-08-19Kumar NeilSell100$85.658.56K
2026-08-18Kumar NeilSell1.90K$81.15154.18K
2026-08-18Kumar NeilSell17.28K$82.211.42M
2026-08-18Kumar NeilSell14.60K$82.991.21M
2026-08-18Kumar NeilSell1.20K$83.77100.44K
2026-08-16Trimarchi ThomasSell22.78K$79.861.82M
2026-08-16Kumar NeilBuy6.52K——
2026-08-16Kumar NeilBuy11.55K——
2026-08-16Kumar NeilBuy19.60K——
2026-08-16Kumar NeilSell36.24K$79.862.89M
2026-08-16Kumar NeilBuy33.54K——
2026-08-16Kumar NeilSell19.60K——
2026-08-16Kumar NeilSell11.55K——
2026-08-16Kumar NeilSell6.52K——
2026-08-16Kumar NeilSell33.54K——
2026-08-16Apuli MaricelSell4.71K$79.86376.46K
2026-07-30Apuli MaricelSell2.00K$80.06160.12K
2026-07-09Ellis AndreaBuy17.17K$16.75287.55K
2026-07-09Ellis AndreaSell17.17K$84.001.44M
2026-07-09Ellis AndreaSell17.17K$16.75287.55K
2026-07-09Cook Jennifer E.Buy17.17K$16.75287.55K
2026-07-09Cook Jennifer E.Buy112.42K$29.003.26M
2026-07-09Cook Jennifer E.Sell36.17K$84.003.04M
2026-07-09Cook Jennifer E.Buy19.00K$8.45160.55K
2026-07-09Cook Jennifer E.Sell112.42K$90.0010.12M
2026-07-09Cook Jennifer E.Sell17.17K$16.75287.55K
2026-07-09Cook Jennifer E.Sell112.42K$29.003.26M
2026-07-09Cook Jennifer E.Sell19.00K$8.45160.55K
2026-06-24Cook Jennifer E.Buy17.17K$16.75287.55K
2026-06-24Cook Jennifer E.Buy20.00K$8.45169.00K
2026-06-24Cook Jennifer E.Sell20.00K$8.45169.00K
2026-06-24Cook Jennifer E.Sell17.17K$16.75287.55K
2026-06-24Cook Jennifer E.Sell37.17K$70.002.60M
2026-06-23Cook Jennifer E.Sell2.20K$68.57150.58K
2026-06-23Valantine HannahSell2.20K$68.57150.58K
2026-06-22Cook Jennifer E.Buy3.99K——
2026-06-22Cook Jennifer E.Buy5.28K$68.92363.69K
2026-06-22Valantine HannahBuy2.81K$41.73117.18K
2026-06-22Valantine HannahBuy3.99K——
2026-06-22Valantine HannahSell2.81K$68.00190.94K
2026-06-22Valantine HannahSell2.81K$41.73117.18K
2026-06-22Valantine HannahBuy5.28K$68.92363.69K
2026-06-22Lo AndrewBuy3.99K——
2026-06-22Lo AndrewBuy5.28K$68.92363.69K
2026-06-22HOMCY CHARLES JBuy3.99K——
2026-06-22HOMCY CHARLES JBuy5.28K$68.92363.69K
2026-06-22AGUIAR ERICBuy3.99K——
2026-06-22AGUIAR ERICBuy5.28K$68.92363.69K
2026-06-22DANIELS RONALD JBuy3.99K——
2026-06-22DANIELS RONALD JBuy5.28K$68.92363.69K
2026-06-22Ellis AndreaBuy3.99K——
2026-06-22Ellis AndreaBuy5.28K$68.92363.69K
2026-06-22Hassan FredBuy3.99K——
2026-06-22Hassan FredBuy5.28K$68.92363.69K
2026-06-22MOMTAZEE JAMES CBuy3.99K——
2026-06-22MOMTAZEE JAMES CBuy5.28K$68.92363.69K
2026-06-22MCCORMICK FRANKBuy3.99K——
2026-06-22MCCORMICK FRANKBuy5.28K$68.92363.69K
2026-06-22Dachille Douglas A.Buy3.99K——
2026-06-22Dachille Douglas A.Buy5.28K$68.92363.69K
2026-06-22Satvat Ali J.Buy3.99K——
2026-06-22Satvat Ali J.Buy5.28K$68.92363.69K
2026-06-20HOMCY CHARLES JSell788$66.2752.22K
2026-06-15Cook Jennifer E.Buy17.17K$16.75287.55K
2026-06-15Cook Jennifer E.Buy65.92K$8.45557.03K
2026-06-15Cook Jennifer E.Sell65.92K$8.45557.03K
2026-06-15Cook Jennifer E.Sell17.17K$16.75287.55K
2026-06-15Cook Jennifer E.Sell88.74K$66.625.91M
2026-06-15Cook Jennifer E.Sell1.50K$67.14100.92K
2026-06-05Kumar NeilSell7.15K$67.20480.34K
2026-06-05Kumar NeilSell8.44K$67.88572.74K
2026-06-05Kumar NeilSell4.42K$68.96304.46K
2026-06-05Kumar NeilSell7.15K$67.20480.27K
2026-06-05Kumar NeilSell8.44K$67.88572.74K
2026-06-05Kumar NeilSell4.42K$68.96304.52K
2026-06-04Kumar NeilSell2.20K$65.72144.58K
2026-06-04Kumar NeilSell1.43K$66.7295.35K
2026-06-04Kumar NeilSell15.92K$67.741.08M
2026-06-04Kumar NeilSell450$68.2730.72K
2026-06-04Kumar NeilSell2.20K$65.72144.58K
2026-06-04Kumar NeilSell1.43K$66.7295.35K
2026-06-04Kumar NeilSell15.92K$67.741.08M
2026-06-04Kumar NeilSell450$68.2730.72K
2026-05-21Kumar NeilSell2.26K$67.57152.43K
2026-05-21Kumar NeilSell6.72K$68.30459.33K
2026-05-21Kumar NeilSell5.07K$69.22351.10K
2026-05-21Kumar NeilSell11.25K$70.48792.92K
2026-05-21Kumar NeilSell800$70.9256.74K
2026-05-18Trimarchi ThomasSell10.46K$64.82677.71K
2026-05-18Trimarchi ThomasSell3.19K$65.95210.71K
2026-05-16Trimarchi ThomasSell22.78K$66.131.51M
2026-05-16Kumar NeilBuy6.52K——
2026-05-16Kumar NeilBuy11.55K——
2026-05-16Kumar NeilBuy19.60K——
2026-05-16Kumar NeilSell36.24K$66.132.40M

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 360, holders -156 vs prior quarter. Ownership 50.69%.

HolderSharesChangeChange %Value
BLACKROCK, INC.10.39M101.53K+0.99%683.58M
KOHLBERG KRAVIS ROBERTS & CO. L.P.8.26M-5.00M-37.70%543.57M
VANGUARD CAPITAL MANAGEMENT LLC7.91M15.13K+0.19%520.75M
VANGUARD PORTFOLIO MANAGEMENT LLC7.49M-171.52K-2.24%492.53M
STATE STREET CORP4.98M541.23K+12.20%327.50M
INVESCO LTD.4.32M615.96K+16.64%284.05M
JPMORGAN CHASE & CO4.00M1.60M+66.80%264.48M
FRANKLIN TEMPLETON INC3.28M1.12M+51.79%255.40M
UBS GROUP AG3.86M2.11M+119.87%254.22M
GEODE CAPITAL MANAGEMENT, LLC3.28M-139.57K-4.08%215.81M
JANE STREET GROUP, LLC3.10M170.11K+5.80%204.26M
AISLING CAPITAL MANAGEMENT LP3.09M-1.50M-32.68%203.30M
UBS GROUP AG2.52M766.05K+43.60%166.03M
MANUFACTURERS LIFE INSURANCE COMPANY, THE1.95M-4.99K-0.26%128.36M
SC US (TTGP), LTD.1.86M00.00%122.41M
PRIMECAP MANAGEMENT CO/CA/1.70M1.70MNew111.82M
PICTET ASSET MANAGEMENT HOLDING SA1.69M242.70K+16.76%111.29M
CITIGROUP INC1.68M1.68MNew110.31M
FMR LLC1.67M-389.37K-18.89%110.01M
LAURION CAPITAL MANAGEMENT LP1.29M-64.06K-4.74%84.76M
MORGAN STANLEY1.27M-420.00K-24.80%83.81M
VANGUARD FIDUCIARY TRUST CO1.13M9.59K+0.86%74.13M
FIL LTD1.03M1.03MNew67.75M
JANE STREET GROUP, LLC1.01M-1.93M-65.61%66.39M
GW&K INVESTMENT MANAGEMENT, LLC955.09K-170.04K-15.11%62.84M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener